Show simple item record

dc.contributor.authorLindegaard, H M
dc.contributor.authorJohansen, P
dc.contributor.authorGröndal, G
dc.contributor.authorJensen, E C
dc.contributor.authorJuul, L
dc.contributor.authorSchlemmer, A M
dc.contributor.authorAgular, B
dc.contributor.authorHansen, Imj
dc.date.accessioned2016-06-30T14:19:44Z
dc.date.available2016-06-30T14:19:44Z
dc.date.issued2016-07
dc.date.submitted2016
dc.identifier.citationDoubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious. 2016, 45 (4):262-6 Scand. J. Rheumatol.en
dc.identifier.issn1502-7732
dc.identifier.pmid26727655
dc.identifier.doi10.3109/03009742.2015.1112030
dc.identifier.urihttp://hdl.handle.net/2336/615145
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractTo investigate the impact of enhanced infusion rate of tocilizumab on the occurrence of infusion reactions, overall safety, and efficacy in rheumatoid arthritis (RA).
dc.description.abstractWe conducted a 24-week multicentre, open-label, randomized parallel group study comparing adverse event (AE) and effect profiles following tocilizumab IV 8 mg/kg every 4 weeks over 31 min vs. standard 60-min infusions in patients with RA and an inadequate clinical response to disease-modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF)-α inhibitors.
dc.description.abstractA total of 47 patients were enrolled in the study and randomized to fast infusions (n = 25) and controls (n = 22). Incidences of infusion reactions were similar between the two groups, neither of them leading to withdrawal. Likewise, the incidence of additional AEs did not differ between the treatment arms. Two serious adverse events (SAEs) were reported, in the control group. Four patients withdrew due to AEs, two from each arm. Efficacy at week 24 was comparable between groups.
dc.description.abstractIn RA, monthly tocilizumab infusions of 8 mg/kg provided over 31 or 60 min during 24 weeks did not differ concerning safety or efficacy.
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://dx.doi.org/ 10.3109/03009742.2015.1112030en
dc.relation.urlhttp://www.tandfonline.com/doi/pdf/10.3109/03009742.2015.1112030en
dc.rightsArchived with thanks to Scandinavian journal of rheumatologyen
dc.subjectLiðagigten
dc.subjectLyfjameðferðen
dc.subjectRHE12
dc.subject.meshArthritis, Rheumatoid/drug therapyen
dc.subject.meshAntibodies, Monoclonal, Humanizeden
dc.subject.meshTreatment Outcomeen
dc.subject.meshSafetyen
dc.subject.meshAntirheumatic Agents/therapeutic useen
dc.titleDoubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious.en
dc.typeArticleen
dc.contributor.department[ 1 ] Odense Univ Hosp, Dept Rheumatol, Sdr Blvd 29, DK-5000 Odense, Denmark [ 2 ] Holbaek Cent Hosp, Holbaek, Denmark [ 3 ] Landspitali Univ Hosp, Reykjavik, Iceland   Organization-Enhanced Name(s)      Landspitali National University Hospital [ 4 ] Frederiksberg Univ Hosp, Frederiksberg, Denmark [ 5 ] Gentofte Univ Hosp, Gentofte, Denmark [ 6 ] Aalborg Univ Hosp, Aalborg, Denmark [ 7 ] Roche AS, Hvidovre, Denmark [ 8 ] Svendborg Hosp, Svendborg, Denmarken
dc.identifier.journalScandinavian journal of rheumatologyen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractTo investigate the impact of enhanced infusion rate of tocilizumab on the occurrence of infusion reactions, overall safety, and efficacy in rheumatoid arthritis (RA).
html.description.abstractWe conducted a 24-week multicentre, open-label, randomized parallel group study comparing adverse event (AE) and effect profiles following tocilizumab IV 8 mg/kg every 4 weeks over 31 min vs. standard 60-min infusions in patients with RA and an inadequate clinical response to disease-modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF)-α inhibitors.
html.description.abstractA total of 47 patients were enrolled in the study and randomized to fast infusions (n = 25) and controls (n = 22). Incidences of infusion reactions were similar between the two groups, neither of them leading to withdrawal. Likewise, the incidence of additional AEs did not differ between the treatment arms. Two serious adverse events (SAEs) were reported, in the control group. Four patients withdrew due to AEs, two from each arm. Efficacy at week 24 was comparable between groups.
html.description.abstractIn RA, monthly tocilizumab infusions of 8 mg/kg provided over 31 or 60 min during 24 weeks did not differ concerning safety or efficacy.


This item appears in the following Collection(s)

Show simple item record